MSF’s response to ViiV’s announcement for not pursuing a deal for its HIV drug with generics

With the TRIPS Waiver negotiations formally resuming this week at the World Trade Organization, MSF called on the EU, the UK and Switzerland to swiftly adopt the landmark Waiver, which would lift intellectual-property monopolies on ...

MSF response to the World Health Organization (WHO) announcement that Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia will be the first recipients of technology from the COVID-19 mRNA technology transfer hub.

MSF and South Africa’s People’s Health Movement also call for long overdue patent law reform

MSF calls on governments to ensure patent monopolies do not block access to new WHO-recommended COVID-19 drug baricitinib

MSF responds to US FDA emergency use authorisation of oral drug molnupiravir for treating people with COVID-19.

With vaccination rates lagging behind in many parts of the world, people are left unprotected against COVID-19 and access to recommended, easy-to-administer medicines is critical.

In light of the shockingly low vaccination rates in South Africa and other African countries, seven organizations from South Africa have sent a letter appealing for the German government to support the immediate suspension of patents ...

As the omicron variant spreads, MSF calls on Moderna and Pfizer-BioNTech to immediately share their lifesaving mRNA vaccine technology with manufacturers that stand ready to boost the global supply

MSF response to Gavi investment in rollout of RTS,S malaria vaccine

MSF and supporters urge high-income countries blocking the landmark TRIPS Waiver to put proclaimed global solidarity into practice and support the Waiver now

MSF welcomes the announcement by the World Health Organization (WHO) COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) of the first global, non-exclusive and transparent voluntary license for a COVID-19 ...

Pfizer recently shared positive interim results for its COVID-19 oral antiviral investigational candidate PF-07321332 in combination with ritonavir (Paxlovid), which is considered a promising treatment, pending regulatory review, WHO ...

Response to Moderna putting profit before global public health, MSF tells the corporation to share mRNA vaccine technology and know-how through the World Health Organization's COVID-19 mRNA vaccine technology transfer hub in South ...

Today the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) announced the approval of molnupiravir for the early treatment of people with mild to moderate COVID-19 who are at increased risk of developing severe disease.

BionTech is bypassing the World Health Organization’s (WHO) mRNA vaccine tech transfer hub in South Africa.

First-ever voluntary license to patent pool in the pandemic does not go far enough.

Following another misleading attempt by the EU to undermine the TRIPS Waiver, MSF calls on the EU stop derailing and support the original Waiver proposal being led by India and South Africa.

After release of WHO Global TB Report 2021, MSF calls on Cepheid to make TB diagnostic tests more accessible to close the deadly TB testing gap.

Protests at embassies in South Africa call for EU countries to stop blocking the TRIPS Waiver on COVID-19 medical tools and US to step up support.